Jax DiEugenio

Single-agent mosunetuzumab generated response rates in patients with relapsed/refractory MCL who previously received a BTK inhibitor.

The FDA granted orphan drug designation to rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases from lung cancer.

MT-8421, a novel engineered toxin body targeting CTLA-4, was not associated with grade 4 or 5 toxicities in patients with select advanced solid tumors.

ALISCA-Breast1 is investigating alisertib plus endocrine therapy in HR-positive, HER2-negative recurrent or metastatic breast cancer.

The Chinese NMPA has approved sacituzumab tirumotecan for EGFR-mutant advanced NSCLC following progression on an EGFR TKI and chemotherapy.

Preliminary data showed atirmociclib plus letrozole yielded antitumor activity in HR-positive/HER2-negative metastatic breast cancer.

A post hoc analysis of the NATALEE trial suggests that ribociclib dose reduction preserves iDFS in hormone receptor+/HER2-negative early breast cancer.

Versamune HPV plus PDS01ADC and bintrafusp alfa demonstrated clinical benefit in locally advanced or metastatic HPV-associated cancers.

Matthew Wagar, MD, discusses treatment considerations for advanced/recurrent endometrial cancer.

SON-1010 is being investigated for its potential to improve outcomes in solid tumors.

The FDA has approved 2 denosumab biosimilars for all indications of their respective reference medications.

Lisaftoclax plus azacitidine demonstrated clinical activity and was safe in higher-risk MDS.

CHMP has recommended glofitamab plus gemcitabine and oxaliplatin for R/R DLBCL.

The CHMP has issued a positive opinion for linvoseltamab in relapsed/refractory multiple myeloma.

Step-up dosing with etentamig produced responses and low rates of CRS in relapsed/refractory multiple myeloma.

Mohammed Najeeb Al Hallak, MD, MS explores treatment considerations in advanced pancreatic, colorectal, and neuroendocrine cancers.

Odronextamab produced durable responses in relapsed/refractory diffuse large B-cell lymphoma after disease progression following CAR T-cell therapy.

Mohammed Najeeb Al Hallak, MD, MS, discusses patient-specific factors to consider during the selection of frontline systemic therapy for HCC.

The Ministry of Health, Labour, and Welfare in Japan has approved epcoritamab for relapsed or refractory follicular lymphoma.

The FDA has granted priority review to zongertinib for unresectable or metastatic HER2-mutant advanced NSCLC.

Christopher L. Moertel, MD, discusses the FDA approval of mirdametinib for patients with neurofibromatosis type 1–associated plexiform neurofibromas.

Kelly E. McCann, MD, PhD, discusses how novel ADCs and targeted therapies could improve treatment strategies in HER2-positive breast cancer.

Piflufolastat F18 imaging impacted treatment decisions and was associated with clinician confidence in prostate cancer management.

Updated results further supported the feasibility of VEGFR TKI interruption and immunotherapy maintenance in advanced renal cell carcinoma.

Avelumab first-line maintenance improved survival outcomes in advanced urothelial carcinoma, regardless of diabetes status.

Nivolumab plus relatlimab did not improve recurrence-free survival vs nivolumab in resected stage III/IV melanoma.

OPN-6602, a small molecule EP300/CBP inhibitor, received orphan drug designation for multiple myeloma.

Venetoclax plus obinutuzumab led to higher undetectable minimal residual disease rates in previously untreated chronic lymphocytic leukemia.

Acalabrutinib plus venetoclax and obinutuzumab demonstrated antitumor activity with a manageable safety profile in mantle cell lymphoma.

Alvaro Alencar, MD, discusses the preliminary efficacy and safety of NX-5948, a BTK degrader, in patients with chronic lymphocytic leukemia.